Low Carbohydrate Small Intestine Study
Studying the Impact of a Low Carbohydrate Diet on the Small Intestinal Microbiota
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Additionally to stoma fluids which will be analyzed for their microbiota composition the investigators will also collect skin samples to analyze for microbiota composition and urine to analyze for metabolite composition.
Low carbohydrate diet will allow for consumption of 80g complex carbohydrates per day, simple sugars will have to be avoided completely
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Benjamin Misselwitz, Prof. Dr. med.
- Phone Number: +41 31 632 59 00
- Email: benjamin.misselwitz@dbmr.unibe.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Inselspital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ileostomy or colostomy
- Good general health
- Written informed consent
Exclusion Criteria:
- Major metabolic diseases that prevent adherence to low carbohydrate diet
- Participation in other clinical trial interfering with study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: All study participants
All participants will undergo sample collection during their regular diet and after modification of their diet to a low carbohydrate diet
|
Participants will reduce their carbohydrate consumption to 80g daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of microbiota profile by 16S sequencing before and after diet modification for significant differences
Time Frame: 28 days
|
Sample content will be measured by 16S sequencing, ecological distances will be assessed by beta-diversity
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative changes of total metabolite abundance in urine
Time Frame: 28 days
|
The whole metabolite composition will be assessed by an untargeted screen done with mass spectrometry
|
28 days
|
|
Analysis of microbiota metabolic potential (microbiome DNA coding for enzymes) after shotgun sequencing
Time Frame: 28 days
|
The total DNA content of the samples will be annotated for for known metabolic active enzymes to assess functionality
|
28 days
|
|
Analysis of microbiota biomass
Time Frame: 28 days
|
The samples will be analysed for the number of bacteria present in them
|
28 days
|
|
Changes of further metagenomic microbiome composition (viral, eucaryotic DNA)
Time Frame: 28 days
|
The DNA of the samples will be screened for parts belonging to viruses or eucaryotic cells
|
28 days
|
|
Culturing of microbiota if appropriate (in vitro)
Time Frame: 28 days
|
If of interest, culturing of specific bacterial strains will be attempted in vitro with the aim to recreate in vivo observations
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Benjamin Misselwitz, Prof. Dr. med., University Clinic for Visceral Surgery and Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2021-01262
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.